Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Model-based drug development applied to oncology.
Barrett JS, Gupta M, Mondick JT. Barrett JS, et al. Among authors: gupta m. Expert Opin Drug Discov. 2007 Feb;2(2):185-209. doi: 10.1517/17460441.2.2.185. Expert Opin Drug Discov. 2007. PMID: 23496077
Challenges and Opportunities With Oncology Drug Development in China.
Bajaj G, Gupta M, Wang HH, Barrett JS, Tan M, Rupalla K, Bertz R, Sheng J. Bajaj G, et al. Among authors: gupta m. Clin Pharmacol Ther. 2019 Feb;105(2):363-375. doi: 10.1002/cpt.1017. Epub 2018 Mar 8. Clin Pharmacol Ther. 2019. PMID: 29328503 Review.
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. Bender BC, et al. Among authors: gupta m. Cancer Chemother Pharmacol. 2012 Oct;70(4):591-601. doi: 10.1007/s00280-012-1934-7. Epub 2012 Aug 12. Cancer Chemother Pharmacol. 2012. PMID: 22886072 Clinical Trial.
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A. Girish S, et al. Among authors: gupta m. Cancer Chemother Pharmacol. 2012 May;69(5):1229-40. doi: 10.1007/s00280-011-1817-3. Epub 2012 Jan 20. Cancer Chemother Pharmacol. 2012. PMID: 22271209 Free PMC article. Clinical Trial.
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S. Gupta M, et al. J Clin Pharmacol. 2012 May;52(5):691-703. doi: 10.1177/0091270011403742. Epub 2011 Sep 27. J Clin Pharmacol. 2012. PMID: 21953571 Clinical Trial.
8,275 results